Anton Rx Report

The FDA recently approved a new therapy, Saphnelo (anifrolumab-fnia) from AstraZeneca, as a treatment for adults with systemic lupus erythematosus (SLE) who are receiving standard

The FDA recently approved a new ORAL therapy, Bylvay (odevixibat) from Albireo Pharma, with an indication for treating pruritus in all subtypes of progressive familial

One of my favorite topics…. Hospitals and health systems opening their own specialty pharmacies (HSSPs). We’ve written about this growing trend for several years, but

The FDA recently approved a new ORAL therapy, Rezurock (belumosudil) from Kadmon Pharmaceuticals, with an indication for adult and pediatric patients with chronic graft-versus-host disease

We’ve often written about the legal pitfalls that specialty pharmacies may encounter that end up costing them financially (HIPAA violations are top of mind). Today

Earlier this month the FDA approved a ‘new’ combination therapy, Darzalex Faspro (daratumumab and hyaluronidase-fihj), from Janssen Biotech. Darzalex was originally approved in 2015 with

It’s about time.It has been quite a while since we’ve heard about a specialty pharmacy acquisition. Over recent years there was a race to the

The public relations battle surrounding White Bagging is heating up.Who’s on each side?Depends on who you ask….!On one side, hospitals are claiming that their very

Here’s something that you don’t see every day….. We published the report below in November 2019 detailing the approval of Exservan, a drug first approved

We missed one….!The drug being recapped today was approved back in late February. We put it on the shelf till we could determine whether this